Phase II study of S-1, leucovorin plus bevacizumab in refractory colorectal cancer

Phase II study of S-1, leucovorin plus bevacizumab in refractory colorectal cancer - Phase II study of S-1, leucovorin plus bevacizumab in refractory colorectal cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000009083

Enrollment

Registered

2012-10-11

Start date

2012-10-12

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal cancer

Interventions

Oral S-1, leucovorin plus bevacizumab therapy

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: (1) Histopathologically confirmed, unresectable colorectal adenocarcinoma (2) Failed prior 5FU, oxaliplatin, irinotecan, bevacizumab and anti-EGFR antibody if KRAS wild type (3) Measurable disease (RECIST ver.1.1) (4) ECOG performance status 0-2 (5) Age of 20 years or older. (6) No prior therapy with S-1 (7) Adequate organ function (8) Written informed concent

Exclusion criteria

Exclusion criteria: (1) Patient with symptomatic brain metastases (2) Massive pleural or paricardial effusion, ascites that required drainage (3) Severe proteinuria (4) Severe comorbidity (5) Pregnant or possibly pregnant, and nursing women (6) Other conditions not suitable for this study

Design outcomes

Primary

Measure	Time frame
Disease control rate assessed by independent review committee	—

Secondary

Measure	Time frame
Disease control rate assessed by investigator, response rate, overall survival, progression free survival, toxicity, QOL	—

Countries

Japan

Contacts

Public ContactKazuhisa Yamaguchi

Aichi Cancer Center Hospital Department of Clinical Oncology

052-762-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026